Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $275000.0.

  • Exagen's Capital Expenditures rose 8707.48% to $275000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $945000.0, marking a year-over-year increase of 9894.74%. This contributed to the annual value of $717000.0 for FY2024, which is 1340.58% down from last year.
  • According to the latest figures from Q3 2025, Exagen's Capital Expenditures is $275000.0, which was up 8707.48% from $146000.0 recorded in Q2 2025.
  • Exagen's Capital Expenditures' 5-year high stood at $1.7 million during Q1 2022, with a 5-year trough of $2000.0 in Q3 2023.
  • Its 5-year average for Capital Expenditures is $464736.8, with a median of $324000.0 in 2023.
  • Per our database at Business Quant, Exagen's Capital Expenditures tumbled by 9977.25% in 2023 and then skyrocketed by 725000.0% in 2024.
  • Quarter analysis of 5 years shows Exagen's Capital Expenditures stood at $1.1 million in 2021, then plummeted by 61.84% to $406000.0 in 2022, then crashed by 73.89% to $106000.0 in 2023, then skyrocketed by 228.3% to $348000.0 in 2024, then dropped by 20.98% to $275000.0 in 2025.
  • Its last three reported values are $275000.0 in Q3 2025, $146000.0 for Q2 2025, and $176000.0 during Q1 2025.